Latest News

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

CAMBRIDGE, Mass. — Biogen’s top scientist offered unflinching support Thursday for the efficacy of the company’s controversial Alzheimer’s drug called aducanumab, shrugging off outside skepticism and almost daring regulators not to approve it.

“I believe the drug works,” said Dr. Al Sandrock, Biogen’s head of research and development and chief medical officer, speaking at the STAT Summit. “I’m very excited about the prospect of getting the drug approved.”

Read the rest…

Source link

Related posts

New tool may help predict the best treatment for multiple myeloma


Cooking During And After Quarantine Is Good For Your Mental Health


Study uncovers potential drug to treat ciliopathies


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World